Gliclazide + Metformin Tablet Franchise in Ahmedabad

Anti-Diabetic Combination Tablet Supplier in Bangalore

Dual Therapy Diabetes Tablet Distributor in Hyderabad

Oral Anti-Diabetic Tablet Franchise Opportunity in Jaipur

Type-2 Diabetes Medicine Stockist in Mumbai
Anti-Diabetic Tablet Export & Manufacturing in Chandigarh

Home/Products /gliclazide-40mg-metformin-500mg-tablet

Glizamide M 40 Tablet

Composition : Gliclazide (40mg) + Metformin (500mg) Tablet

Dosage Form : Tablet

Packaging Type : Blister

Packaging : 10*10

Price : ₹0/-

Glizamide M 40 Tablet contains Gliclazide 40mg and Metformin 500mg, offering a balanced dual-action approach for managing type-2 diabetes mellitus. It is ideal for patients who require combination therapy to achieve optimal glycemic control.

Gliclazide stimulates pancreatic insulin release, while Metformin enhances insulin sensitivity and reduces hepatic glucose production. Together, they provide effective control of fasting and postprandial blood sugar levels.

This combination is suitable for patients inadequately controlled on monotherapy or lifestyle interventions alone, offering proven efficacy with a favorable safety profile. Its oral administration and convenient dosing promote adherence in long-term diabetes management.

Adding Glizamide M 40 Tablet to your diabetes and metabolic-care portfolio strengthens your offerings, unlocking opportunities in retail pharmacies, hospital supply, institutional distribution, export channels, and third-party manufacturing. Its high prescription rate ensures continuous demand and strong commercial performance.

Read More

About the Product

Glizamide M 40 Tablet contains Gliclazide 40mg and Metformin 500mg, offering a balanced dual-action approach for managing type-2 diabetes mellitus. It is ideal for patients who require combination therapy to achieve optimal glycemic control.

Gliclazide stimulates pancreatic insulin release, while Metformin enhances insulin sensitivity and reduces hepatic glucose production. Together, they provide effective control of fasting and postprandial blood sugar levels.

This combination is suitable for patients inadequately controlled on monotherapy or lifestyle interventions alone, offering proven efficacy with a favorable safety profile. Its oral administration and convenient dosing promote adherence in long-term diabetes management.

Adding Glizamide M 40 Tablet to your diabetes and metabolic-care portfolio strengthens your offerings, unlocking opportunities in retail pharmacies, hospital supply, institutional distribution, export channels, and third-party manufacturing. Its high prescription rate ensures continuous demand and strong commercial performance.

Some patients may experience nausea, diarrhea, abdominal discomfort, dizziness, or headache. Hypoglycemia may occur due to Gliclazide. Rarely, lactic acidosis, urinary tract infections, or allergic reactions may occur.

Glizamide M 40 Tablet is indicated for the management of type 2 diabetes mellitus in patients who require combination therapy for effective glycemic control when diet and exercise alone are insufficient.

Use strictly under medical supervision. Monitor blood glucose regularly to prevent hypoglycemia. Avoid use in patients with severe renal or hepatic impairment. Follow the prescribed dosage and lifestyle recommendations carefully.

Store in a cool, dry place below 25°C, protected from light and moisture. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation